Telithromycin: A once-daily, broad-spectrum ketolide for treatment of various respiratory infections

Formulary

Volumn 36, Issue 2, 2001, Pages 101-110

  Preston, S L ^a   Drusano, G L ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFUROXIME; CLARITHROMYCIN; DIGOXIN; ERYTHROMYCIN; ETHINYLESTRADIOL; KETOCONAZOLE; KETOLIDE; LEVONORGESTREL; MACROLIDE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PENICILLIN V; RANITIDINE; TELITHROMYCIN; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MAXILLA SINUSITIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHARMACODYNAMICS; PHARYNGITIS; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; TONSILLITIS; VERTIGO;

EID: 0035107804     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Macrolides
2. Chemistry and mode of action of macrolides
3. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification
4. Ketolides lack inducibility properties of MLS(B) resistance phenotype
5. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
6. Susceptibilities of penicillinand erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
7. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
8. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae
9. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
10. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
11. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against grampositive bacteria
12. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans
13. Pharmacokinetics of 800-mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers
14. The macrolides: Erythromycin, clarithromycin, and azithromycin
15. Dose proportionality of the pharmacokinetics of HMR 3647, a new ketolide antimicrobial, in healthy adult males
16. The bioavailability of telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, is unaffected by food
17. Telithromycin (HMR 3647), a new ketolide antimicrobial, is metabolised and excreted mainly in faeces in man
18. Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses
19. Pharmacokinetic and clinical studies of a new ketolide antimicrobial, telithromycin (HMR 3647), in otorhinolaryngology
20. Telithromycin (HMR 3647) penetrates rapidly into tonsillar tissue achieving high and prolonged tonsillar concentrations
21. Telithromycin (HMR 3647), the first ketolide antimicrobial, does not require dosage adjustment in individuals with hepatic impairment
22. In vivo pharmacodynamic activity of HMR 3647, a new ketolide
23. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae
24. Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP)
25. Efficacy of telithromycin (HMR 3647), a new once-daily antimicrobial, in the treatment of community-acquired pneumonia
26. A prediction rule to identify low-risk patients with community-acquired pneumonia
27. Efficacy and tolerability of telithromycin (HMR 3547) vs high-dose amoxicillin in the treatment of community-acquired pneumonia
28. Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community acquired pneumonia (CAP) in adults
29. Oral telithromycin (HMR 3647) 800 mg once daily
30. Efficacy of the ketolide telithromycin (HMR 3647) in the treatment of bacteremia associated with community-acquired pneumonia
31. Efficacy of telithromycin (HMR 3647), a new once-daily ketolide, in community-acquired pneumonia caused by atypical pathogens
32. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD
33. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis (AECB)
34. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis
35. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid 500/125 mg three times daily for 10 days in acute maxillary sinusitis (AMS) in adults
36. Efficacy of 5 days' telithromycin (HMR 3647) vs 10 days' penicillin V in the treatment of pharyngitis in adults
37. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as oral clarithromycin 250 mg twice daily for 10 days in group A β-hemolytic streptococcal (GABHS) pharyngitis/tonsillitis
38. HMR 3647, a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives
39. High in vitro susceptibility of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens